Navigation Links
Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
Date:10/27/2009

NEW YORK, Oct. 27 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., today announced positive results from a 165 patient, placebo controlled, double-blind Phase II clinical trial of INT-747 in patients with primary biliary cirrhosis (PBC). The study evaluated the effects of adding one of three doses of INT-747 or placebo to ursodeoxycholic acid (UDCA) therapy in patients who did not respond adequately to UDCA therapy alone. All three doses of INT-747 added to UDCA produced a statistically highly significant reduction in alkaline phosphatase (Alk Phos) levels, the primary endpoint at the end of the 12-week treatment period, as compared to patients receiving placebo and UDCA. Alk Phos is a liver enzyme routinely used to evaluate the clinical status and disease progression of PBC patients. All the INT-747 doses added to UDCA produced 20% or greater reductions in Alk Phos, with similar significant falls in other clinical liver enzymes. With the exception of a higher incidence of pruritus (itching) in the two top INT-747 dose groups, adverse events were generally similar across all groups.

PBC is a chronic autoimmune disease of the liver marked by the slow progressive destruction of the small bile ducts within the liver, which may lead to liver failure and the need for( )liver transplantation. PBC primarily afflicts women with up to 300,000 patients estimated worldwide.

Keith Lindor, MD, Dean of the Medical School at Mayo Clinic and a key investigator in the study, commented, "UDCA is the only drug currently approved for PBC and it does not adequately treat the disease in many patients. There is a real need for novel therapies and the clinically meaningful results from this study are supportive of INT-747's potential as an effective drug for PBC."

Mark Pruzanski, MD, Intercept's President and Chief Executive Officer, added, "The remarkable performance of INT-747 in this study, together with the previously announced positive
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
2. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
3. BioMarin Acquires Huxley Pharmaceuticals, Inc.
4. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
5. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
7. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
8. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
9. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
10. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
11. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... BETHLEHEM, Pa. , Nov. 21, 2014 /PRNewswire/ ... drug eluting devices, has developed and manufactured a ... Institute (LPRI), the Research and Development arm of ... Vice President of Project Management at Particle Sciences, ... Particle Sciences utilizing our material sciences and modeling ...
(Date:11/22/2014)... , Nov. 21, 2014 Many ... Undoubtedly, the growing influence of patients in the ... marketing interactions. Now, more than ever, understanding how ... for medical products is essential. ... Practices, LLC, benchmarked companies spent about two-thirds of ...
(Date:11/21/2014)... COLLEGE PARK, Md. , Nov. 21, 2014 /PRNewswire-USNewswire/ ... Engineering today will host the ceremonial groundbreaking of the ... Maryland, College Park. The new building will cultivate transformative ... human health.  Taking place at 10:00 a.m. ... building in the Paint Branch Parking Lot, adjacent to ...
Breaking Medicine Technology:Particle Sciences' Clinical Trial Supplies Group Manufactures Innovative Vaginal Ring 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4
... October 25, 2011 International medical ... (NASDAQ OMX Stockholm: SECT B) , announces ... University Hospitals (UH) in Cleveland.   UH and ... medical imaging with the goals of improving patient care, ...
... SUNNYVALE, Calif., Oct. 25, 2011 ... premier radiation oncology company, today announced that the U.S. ... 510(k) clearance to market the Dose Control System (DCS), ... system performance.   The TomoTherapy System revolutionized ...
Cached Medicine Technology:Sectra Signs Medical Imaging Research Agreement With University Hospitals in Cleveland 2Sectra Signs Medical Imaging Research Agreement With University Hospitals in Cleveland 3Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System 2Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System 3
(Date:11/22/2014)... PrettyTailor , an outstanding dress ... big promotion. Customers can buy new dresses at its ... visit its website. , As a matter of fact, ... It mainly provides four types of wedding outfits, including ... girl dresses. It also provides a variety of occasion ...
(Date:11/22/2014)... is a famous brand in the bamboo flooring industry. ... bamboo mats ; the new models are offered now ... According to the sales manager of BambooFlooringChina.com, Bamboo is a ... resource. Their bamboo mats are 100% made from natural bamboo. ... bamboo with caramel bamboo strips. , “Bamboo mats ...
(Date:11/22/2014)... Discount-Dress.com is an important company ... is to increase the company’s online market share by a ... of bridesmaid dresses and announced a bridesmaid dress promotion for ... Dec. 30, 2014. All the dresses from this company are ... In fact, Discount-Dress.com is very good at manufacturing wedding dresses. ...
(Date:11/22/2014)... New York, New York (PRWEB) November 22, 2014 ... use of power morcellators ( http://www.morcellatorlawsuit2015.com ) in ... than 450 new signatures since the end of October, ... people had signed the petition as of November 21st, ... October 31st, when 86,042 supporters had signed on to ...
(Date:11/22/2014)... New York, New York (PRWEB) November 22, 2014 ... been filed on behalf of patients who allegedly developed ... move forward in the federal multidistrict litigation now underway ... Liebhard LLP reports. According to court documents, the litigation ... at 10:00 a.m. The Court has directed Lead Counsel ...
Breaking Medicine News(10 mins):Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3
... $12 million grant from the National Institutes of Health ... medication of choice for preventing migraines in children and ... and adolescents in the United States, with an annual ... FDA-approved medication to prevent childhood migraines and there are ...
... experience more chronic musculoskeletal pain, suggests a new study led ... women over the age of 18 were surveyed on their ... the analysis were fibromyalgia, sciatica, chronic neck pain, chronic back ... all over the body. Results showed that women who ...
... Pediatricians in Appalachia are less likely than doctors in ... the human papillomavirus (HPV) vaccine, according to a new study. ... most important risk factor for cervical cancer and studies ... cancer and to die from it than women living elsewhere. ...
... long been an attractive class of drug candidates because ... potential side effects. Dr. Andrei Yudin, Professor, Department ... and effective process that makes linear peptides circular, which ... effectively and increase their stability compared to linear peptides. ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... colon cancer screening earlier than women, new research suggests. ... have potentially precancerous lesions (also called polyps or adenomas) in ... percent of women -- and to have them at an ...
... documenting patients, preferences for care at the end of life ... A new study published today in the Journal of ... physicians about end-of-life care and have an advance directive in ... do not have these discussions and documents. The study ...
Cached Medicine News:Health News:Cincinnati Children's earns $12 million NIH grant to test migraine prevention medicines 2Health News:Study shows link between smoking and chronic pain in women 2Health News:Pediatricians in Appalachia less likely to recommend HPV vaccine 2Health News:Pediatricians in Appalachia less likely to recommend HPV vaccine 3Health News:OGI and MaRS Innovation invest in peptide therapeutics 2Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 2Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 3
The Dolphin Medical 2150 Pulse Oximeter consists of the Dolphin ONE OEM 701 Module technology, (1) extension cable, and (1) oximetry sensor to non-invasively calculate the functional saturation of ar...
All-in-One Fingertip Oximeter...
... The Invacare Sleep Printing ... specifically designed to address ... a device that can ... conducting overnight screening for ...
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Medicine Products: